DUBLIN, Calif, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that it will release its 2012 third quarter financial results on Tuesday, October 30, 2012. James S.J. Manuso, PhD, chairman and chief executive officer, and the Astex Pharmaceuticals management team will provide details of the Company's financial results and any revised outlook for the future.
A press release will be issued following the close of the market on October 30th. The Company will host a webcast conference call to discuss the results at 4:30 p.m. ET. A live webcast of the call may be accessed through the Events Calendar in the Investors section of the Company's website at www.astx.com . A webcast replay of the conference call will be available shortly following the event. Alternatively, a replay of the conference call may be accessed by dialing (855) 859-2056 (domestic) and (404) 537-3406 (international); the replay passcode number is 53673255. The webcast replay will be available for 30 days, and the telephone replay will be available for 7 days.
About Astex PharmaceuticalsAstex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales. For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com . The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273
CONTACT: Timothy L. Enns Astex Pharmaceuticals, Inc. Senior Vice President Corporate Communications & Marketing Tel: +1 (925) 560-2810 E-mail: firstname.lastname@example.org Susanna Chau Astex Pharmaceuticals, Inc. Manager Investor Relations Tel: +1 (925) 560-2845 E-mail: email@example.com Alan Roemer The Trout Group Managing Director Tel: +1 (646) 378-2945 E-mail: firstname.lastname@example.org Kari Watson MacDougall Biomedical Communications Senior Vice President Tel: +1 (781) 235-3060 E-mail: email@example.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV